The combination of ruxolitinib and danazol produced hematologic stabilization in patients with myelofibrosis in a small phase 2 study involving 14 individuals.
Investigators looked at the combination’s efficacy and tolerability in high-risk myelofibrosis patients treated at 2 institutions. Among the results:
- Using International Working Group-Myeloproliferative Neoplasms Research and Treatment criteria, responses were stable disease in 9 patients; clinical improvement in 3 (all spleen responses); partial response in 1; and progressive disease in 1.
- Anemia and thrombocytopenia were stabilized.
- 4 of 5 JAK inhibitor naïve patients had stable or increasing hemoglobin.
- 5 of 9 patients on prior JAK inhibitor had stable or increasing hemoglobin levels; 8 experienced stable or increasing platelet levels.
- Grade 3 or greater hematologic toxicity occurred in 10 patients.
- 2 patients experienced non-hematologic toxicity.
Gowin K, Kosiorek H, Dueck A, et al. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. [Published online ahead of print June 13, 2017]. Leuk Res. doi:10.1016/j.leukres.2017.06.005.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al